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Serum response factor (SRF) is a ubiquitously expressed tran-
scription factor that binds a 10-bp element known as the CArG
box, located in the proximal regulatory region of hundreds of
target genes. SRF activates target genes in a cell- and context-
dependent manner by assembling unique combinations of
cofactors over CArG elements. One particularly strong SRF
cofactor, myocardin (MYOCD), acts as a component of amolec-
ular switch for smoothmuscle cell (SMC)differentiationby acti-
vating cytoskeletal and contractile genes harboring SRF-bind-
ing CArG elements. Here we report that the human ACTG2
promoter, containing four conserved CArG elements, displays
SMC-specific basal activity and is highly induced in thepresence
of MYOCD. Stable transfection of a non-SMC cell type with
Myocd elicits elevations in endogenous Actg2 mRNA. Gel shift
and luciferase assays reveal a strong bias for MYOCD-depend-
ent transactivation through CArG2 of the human ACTG2 pro-
moter. Substitution of CArG2 with other CArGs, including a
consensus CArG element, fails to reconstitute full MYOCD-de-
pendentACTG2 promoter stimulation.Mutation of an adjacent
binding site for NKX3.1 reducesMYOCD-dependent transacti-
vation of the ACTG2 promoter. Co-immunoprecipitation, glu-
tathione S-transferase pulldown, and luciferase assays show a
physical and functional association between MYOCD and
NKX3.1; no such functional relationship is evident with the
related NKX2.5 transcription factor despite its interaction with
MYOCD. These results demonstrate the ability of MYOCD to
discriminate among several juxtaposed CArG elements, pre-
sumably through its novel partnership with NKX3.1, to opti-
mally transactivate the human ACTG2 promoter.
Smoothmuscle cell (SMC)6 differentiation requires synchro-
nized expression of general and cell-restricted cytoskeletal and
contractile genes encoding proteins conferring the unique con-
tractile activity of this cell type (1). Many SMC differentiation
genes contain proximal cis regulatory elements, called CArG
boxes, which bind the broadly expressed transcription factor,
serum response factor (SRF) (2). SRF is a weak activator of gene
expression, requiring physical interactions among over 60
cofactors that themselves recruit additional proteins to fully
direct unique patterns of gene expression. The discovery of one
such SRF cofactor, called myocardin (MYOCD), has revolu-
tionized our understanding of the basic transcriptional mecha-
nisms underlying the specification of a differentiated SMCphe-
notype (3). Myocd mRNA is restricted mainly to cardiac and
SMC and its encoded protein is one of nature’s most powerful
transactivators of gene expression (3), although the level of
SMC gene activation appears to be both cell and promoter con-
text-dependent (4). MYOCD elicits structural and functional
attributes of SMC suggesting this cofactor has characteristics of
a master regulator of the differentiated SMC phenotype (5).
Consistent with this idea, conventional inactivation of Myocd
results in midgestational arrest at embryonic day 10.5 of the
mouse because dorsal aortic SMC are poorly differentiated (6),
a finding that has recently been extended to neural crest-de-
rived SMC of the great arteries (7).
In theory, SRF binds up to 1,216 permutations of the CArG
box (8) with the consensus forms (CCW6GG) binding SRF
more avidly than non-consensus forms (9). Many SMC con-
tractile genes contain two or more CArG elements in either
their 5 promoter or intronic regions (2, 10). Olson and col-
leagues (11) proposed a model wherein MYOCD forms a
molecular bridge over two or more CArG boxes by undergoing
homo-oligomerization through its leucine zipper-like domain
thus maximizing transactivation of SMC contractile genes har-
boringmore than one CArG element. According to this model,
SMC cytoskeletal/contractile genes with one CArG box will
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only be activated moderately by MYOCD. On the other hand,
several multi-CArG containing genes are refractory to high
level MYOCD-dependent transactivation, which likely is
attributable to sequences immediately flanking CArG elements
(3, 12–16). Thus, the number of CArG boxes, the sequence
character therein, and flanking sequences appear to be key
determinants of MYOCD-mediated transcriptional activity.
SMC are often defined structurally and physiologically as
vascular or visceral SMC. Although expressing comparable lev-
els of many cytoskeletal/contractile genes, microarray data
indicate unique gene expression signatures between both SMC
types (17). For example, the SRF- and MYOCD-dependent
telokin gene is abundantly expressed in visceral SMCwith low-
level expression in vascular SMC (18). However, a chimeric
promoter of telokin harboring a fragment of the Tagln pro-
moter confers vascular activity in transgenic mice suggesting
that SMC promoters harbor important sequence content for
vascular versus visceral SMC expression (19). Two smoothelin
isoforms exhibit SMC type-restricted expression in adults with
smoothelin A expressed predominantly in visceral SMC and
smoothelin B in vascular SMC (20). Smoothelin A contains con-
served CArG elements that are mildly responsive to MYOCD,
whereas smoothelin B, without conserved CArG boxes, is
refractory to MYOCD transactivation in vitro (15).
Themurine smoothmuscle -actin gene (Actg2) is expressed
abundantly in visceral SMC with lower levels in vascular SMC
(21). Transgenic mice carrying 13.7 kb of 5 promoter and 3
intronic mouse Actg2 sequences similarly exhibit visceral SMC
activity (22). In this report, we have revisited expression of
Actg2 in vascular SMC and evaluated the role of MYOCD in
regulating human ACTG2 promoter activity in vitro. Results
demonstrate Actg2 mRNA and protein expression as well as
specific promoter activity in vascular SMC. Despite the pres-
ence of four closely juxtaposed CArG boxes in the 5 proximal
region of ACTG2, MYOCD appears to preferentially utilize a
single CArG element (CArG2) that confers high-level pro-
moter activity through elevations in SRF-MYOCD binding.
Importantly, an adjacent binding site for NKX3.1 is necessary
for full transactivation, and co-transfection reporter assays of
MYOCD show NKX3.1 potentiates MYOCD-dependent stim-
ulation of the humanACTG2 promoter. Co-immunoprecipita-
tion, GST pulldown, and luciferase reporter assays suggest this
activity occurs through physical contacts between the C-termi-
nal domain of MYOCD and NKX3.1. These results reveal a
CArGbias forMYOCDtransactivation ofActg2 gene transcrip-
tion and suggest this discrimination stems from the novel inter-
action of MYOCD with the NKX3.1 homeodomain protein.
EXPERIMENTAL PROCEDURES
Cell Culture—Primary-derived rat aortic smooth muscle
cells and the PAC-1 and A7r5 SMC lines, as well as NIH 3T3,
CV-1, COS-7, HeLa, BC3H1, L6 myoblasts, and a human uter-
ine SMC line (SKLMS, ATCC) were maintained in Dulbecco’s
modified Eagle’s medium containing high glucose, supple-
mented with 10% fetal bovine serum and 200 M L-glutamine.
Cells were cultured in the absence of antibiotics and antimycot-
ics and used for transfections or RNA/protein analysis when
70–90% confluent. The samemedium conditionswere used for
prostate stromal and epithelial cells as well as LNCaP and PC3
prostate cell lines. In some experiments the androgen, methyl-
trienolone (R1881, PerkinElmer Life Sciences), was used at 1 or
10 nM (see below). For L6 stable cell lines carrying myocardin
(4), cells were cultured in the presence of 900 g/ml G418.
Plasmids—Serial deletions of the human ACTG2 promoter
(285, 205, 95, and 55 nucleotides from the annotated transcrip-
tional start site) were cloned into pGL3 basic (Promega, Madi-
son,WI) for firefly luciferase reporter assays (below).Mutations
were introduced into each of the four CArG regulatory ele-
ments (CArG1, CArG2, CArG3, and CArG4) and NKX-bind-
ing element (NKE) of the human ACTG2 promoter using
QuikChange site-directed mutagenesis (Stratagene) and veri-
fied by DNA sequencing (Cornell Sequencing Core). The
ACTG2 CArG4 sequence was mutated from the wild type
element 5-gcttataagg-3 to 5-gtctataagg-3, the CArG3 se-
quence from 5-gcataaaagg-3 to 5-gtctaaaagg-3, the CArG2
sequence from 5-ccttatatgg-3 to 5-gtctatagg-3, the CArG1
sequence from 5-cctttttagg-3 to 5-gtcttttagg-3, and the NKE se-
quence from 5-cgtcagctgg-3 to 5-cgtcagcccc-3. The CArG1,
-2, -3, -4, CArG1, -3, -4, and CArG2 mutants contained the
same respective mutations as above. Plasmids pcDNA3.
1-FLAG-MYOCD and pcDNA3.1-FLAG-MYOCD-CT were
used as previously described (3). SRF-VP16, pCGN-HA-
NKX2.5, and pCGN-HA-NKX3.1 were used as described
(23, 24).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)—
Total RNA was isolated from tissues and cell lines using the
TRIzol reagent system (Invitrogen). 4 g of total RNA was
reverse transcribed into cDNA with SuperScriptTM III first-
strand synthesis (Invitrogen). PCR amplification was then
performed with the following primers to the mouse genes of
interest: Gapd, forward, gccaaaagggtcatcatctc and reverse,
ggccatccacagtcttct (226 bp);Myocd, forward, cgccaacgacagtga-
cgaaca and reverse, cgtgaagctcagctgcagac (253 bp); Srf, forward,
atcaccaactacctggcacc and reverse, cacctgtagctcggtgaggt (594
and 402 bp); Actg2, forward, catgaagtgtgacattgacatccgc and
reverse, ggcttgaaggttttaatgatctg (356 bp); Acta2, forward, acca-
ccatgtacccaggcattgct and reverse, ccacgagtaacaaatcaaagcttt-
gggc (330 bp);Nkx3.1, forward, tccttcctcatccaggac and reverse,
caggtacttctgatggctg (356 bp); and Nkx2.5, forward, cccttctcag-
tcaaagacatcc, and reverse, gtaccgctgttgcttgaag (451 bp). Adeno-
viral-mediated short hairpin RNA knockdown of SRF was done
in BC3H1 cells using 25multiplicity of infection of short hairpin
SRF or short hairpin enhanced green fluorescent protein con-
trol and levels of the Actg2 transcript were measured with the
above primers. PCR products were resolved in a 1.5% agarose
gel and visualized by ethidium bromide staining.
Transient Transfection and Luciferase Assay—The calcium
phosphate co-precipitation method was used for transient
transfections as described (25). Cells were dispersed in 24-well
plates at 50,000 cells/well and grown to subconfluence. Except
where indicated, cells were co-transfected with 0.5 g of
ACTG2 promoter linked to firefly luciferase and either 0.5g of
empty vector (pcDNA3.1 or pCGN) or an equal molar quantity
of the same vector carrying various forms ofMYOCD,NKX3.1,
NKX2.5, or SRF-VP16. Fifty nanograms of the internal Renilla
reporter gene (Promega) were used in all samples to normalize
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luciferase activity. The following day (12–16 h post-transfec-
tion), cells were washed with phosphate-buffered saline and
refed fresh growth medium for an additional 24 h. Cells were
then lysed with 200 l of 1 Passive lysis buffer (Promega) and
20 l of cell lysate was processed for Dual Luciferase Assay
according to the manufacturer’s manual (Promega). Biolumi-
nescence was measured over 10 s with an AutoLumat LB 953
luminometer (EG&G Berthold, Gaithersburg, MD). All trans-
fections were performed in quadruplicate in at least two inde-
pendent experiments and expressed as the normalized (lucifer-
ase to Renilla) fold-change over baseline (55 ACTG2, see Fig.
2B, and 55 ACTG2 absent MYOCD in see Fig. 3), percent
change under 285 ACTG2 (see Fig. 5), or fold-increase over
pcDNA3.1 or pcGN control vectors (see Fig. 6).
Immunohistochemistry—Sections (5 m) of rat heart and
aorta were processed for immunohistochemistry with an
ACTG2-selective antibody as described (26). Under these con-
ditions (1:500 antibody dilution) we and others have shown
that the monoclonal antibody clone B4 used in this study is
highly selective for the smoothmuscle -actin isoform,ACTG2
(48, 49).
Co-immunoprecipitation and Western Blotting—Interac-
tions between NKX3.1 andMYOCD were examined by co-im-
munoprecipitation following co-transfection with FLAG-
tagged MYOCD and HA-tagged NKX3.1. Transfected cells
were lysed in immunoprecipitation lysis buffer containing 50
mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 0.5% Non-
idet P-40, 1 mM dithiothreitol, 10 mM sodium fluoride, 1 mM
sodium orthovanadate, 200 M phenylmethylsulfonyl fluoride
and protease inhibitormixture (Sigma). Lysateswere cleared by
centrifugation (5 min at 14,000 rpm), followed by incubation
with anti-FLAG antibodies conjugated to agarose beads (M2,
Sigma) overnight at 4 °C. The beads were washed three times
with lysis buffer, the immune complexes were eluted by boiling
in Laemmli buffer for 5min and subjected to polyacrylamide gel
electrophoresis followed by electrotransfer to Immobilon-P
membrane (Millipore). The proteins on the membrane were
then analyzed byWestern blotting with anti-HA or anti-FLAG
antibodies followed by horseradish peroxidase-conjugated sec-
ondary antibodies (Calbiochem), and developed by enhanced
chemiluminescence reagent (Pierce).
In Vitro Binding Assay—The [35S]methionine-labeled in
vitro translated myocardin probe was generated in rabbit
reticulocyte lysate (Promega,Madison,WI), following theman-
ufacturer’s protocol. The [35S]MYOCD probe was incubated
with purified GST-NKX3.1 or GST alone (bound to glutathi-
one-Sepharose beads) for 3 h at 4 °C in a buffer containing 20
mMHEPES, 75mMKCl, 1 mM EDTA, 2 mMMgCl2, 0.1% Non-
idet P-40, 2 mM dithiothreitol. The resin was subsequently
washed four times with 1 ml of the binding buffer, and then
boiled in Laemmli sample buffer. Proteins were resolved by
SDS-PAGE and transferred to a polyvinylidene difluoride
membrane. The proteins on the membrane were stained
with Amido Black, and the [35S]MYOCD was detected by
autoradiography.
Electrophoretic Mobility Shift Assay (EMSA)—To examine
SRF-MYOCD binding to CArG boxes in the human ACTG2
promoter, the following oligonucleotides (CArG andNKE sites
underlined, mutant bases in lowercase) and their respective
complement (not shown) were heated at 65 °C for 10 min and








The wild type ACTG2 205 promoter fragment containing
CArG1, NKE, and CArG2 was end-labeled using T4 polynucle-
otide kinase (New England Biolabs). SRF and MYOCD were in
vitro translated by theTNTCoupled Reticulocyte Lysate system
(Promega). Endogenously expressing MYOCD was from
lysates of L6 cell lines stably transfectedwithMYOCD (4). Sam-
ples were resolved on a 5% polyacrylamide gel using indicated
competitors and antibodies essentially as described (27).
Computational Biology—Comparative sequence analysis of
the human ACTG2 genetic locus with orthologs in chimp (Pan
troglodytes, Ptr), dog (Canis familiaris, Cfa), mouse (Mus mus-
culus, Mmu), and chicken (Gallus gallus, Gga) was done with
the VISTA Gene Alignment tool (28). Sequence logos repre-
senting position weight matrices of orthologous CArG and
NKE elements of the ACTG2 promoter from the same species
as those used in the VISTA analysis were generated with
WebLogo (29). Simple protocols for performing these analyses
are available upon request.
RESULTS
ACTG2 Expression in Vascular Smooth Muscle and Prostate—
Actg2 mRNA is abundantly expressed in aorta, bladder, and
cultured SMCwith less expression in other tissues and cell lines
(Fig. 1A). In contrast, Acta2mRNA is more broadly expressed.
Interestingly, we observe differential splicing of Srf mRNA in
aorta and bladder (primarily full-length) versus other tissues
and cultured SMC (full-length plus 5 splice variant, Fig. 1A);
the molecular basis for this differential splicing phenomenon is
presently unknown. As expected,Nkx2.5mRNA is restricted to
heart but detectable transcripts are also seen in the A7r5 SMC
line (Fig. 1A). Expression of the related Nkx3.1 mRNA is only
seen in L6 myoblasts and A7r5 SMC (the latter cells only show
detectable Nkx3.1 transcripts after two sequential rounds of
PCR).Actg2 andNkx3.1mRNAare present in prostate cell lines
(39). To seewhetherMyocd is similarly co-expressedwith these
transcripts, we measured mRNA levels in several distinct
human prostate cell lines in the absence or presence of andro-
gen. Results reveal detectable transcripts toMyocd in each cell
line (Fig. 1B). Moreover,Myocd is co-expressed with Actg2 and
Nkx3.1mRNA inmouse prostate tissue (Fig. 1C). To determine
whether expression of the ACTG2 protein coincides with its
mRNAexpression in vascular SMC,we performed immunohis-
tochemistry with an ACTG2-selective antibody on sections of
rat heart and aorta. Levels of ACTG2 protein are present in
coronary artery, aortic and microvascular SMC (Fig. 1D, d, e,
and f, respectively), but not cardiomyocytes (Fig. 1D, d) or
perivascular tissue (Fig. 1D, f). Together, the expression data
establish mRNA and protein expression of SM -actin (Actg2)
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in distinct vascular SMC types and the co-expression ofMyocd,
Nkx3.1, and Actg2mRNA in prostate tissue/cell lines.
SMC-specific Basal and MYOCD-dependent Activation of
Actg2—Comparative genomics between human (Hsa) and
chimp (Ptr), dog (Cfa), mouse (Mmu), and chicken (Gga)
reveals high sequence conservation in the immediate 5 pro-
moter region ofACTG2where 4 conservedCArG elements and
a binding element for NK factors (NKE) reside over 200 bp of
genomic DNA (Fig. 2, A and B). The presence of CArG1 and
NKE elements mediates mild basal promoter activity in several
SMC lines from human and rat (95 in Fig. 2C). Inclusion of
CArG2 dramatically elevates basal human ACTG2 promoter
activity in a SMC-specific manner (205 in Fig. 2C). The addi-
tion of CArG3 and CArG4 has no further stimulatory effect on
ACTG2 promoter activity in SMC (285 in Fig. 2C). To deter-
mine the relative effects of MYOCD on each ACTG2 promoter
construct, transient co-transfections were performed in COS7
and the rat pulmonary artery PAC1 SMC line using the 807-
amino acid form ofMYOCD (3) (Fig. 3,A and B). In both COS7
and PAC1 SMC, MYOCD is unable to stimulate increases in
the ACTG2 55 promoter construct above baseline levels and
onlymildly stimulates95ACTG2. However, addition of CArG2
(205) results in 100-fold increases in ACTG2 promoter activ-
ity in COS7 cells (Fig. 3A). Less apparent induction is seen with
205 ACTG2 in PAC1 SMC due to the higher basal activity of
the 205 reporter (Fig. 3B). Similar to data in Fig. 2C, the pres-
enceofCArG3andCArG4 (285) confers no furtherMYOCD-
dependent transactivation of ACTG2 promoter activity (Fig. 3,
A and B). Consistent with previous data using other CArG-de-
pendent promoters (3), the basic and C-terminal transactiva-
tion domain ofMYOCDare essential inmediatingACTG2 pro-
moter stimulation (data not shown). To determine whether the
potent stimulation of MYOCD on the ACTG2 promoter trans-
lates into activation of the endogenous rat Actg2 gene, we eval-
uated mRNA expression levels of Actg2 in L6 myoblasts stably
transfected with Myocd. In three independent stable cell lines,
the presence ofMyocd transcripts correlated with induction of
the Actg2mRNA (Fig. 3C). Moreover, RNA knockdown of SRF
in BC3H1 cells elicits corresponding decreases in endogenous
Actg2 transcripts (Fig. 3D). Together, these results firmly estab-
lish Actg2 as an SRF-MYOCD-dependent SMC target gene,
consistent with previous expression studies (11).
SRF-Myocardin Preferentially Binds CArG2 of the Human
ACTG2 Promoter—A previous study using the chicken Actg2
promoter showed differential binding of SRF to each of the 4
conserved CArG elements (26). We used EMSA to assess the
association ofMYOCDwith SRF bound to CArG1 or CArG2 of
the human ACTG2 205 promoter because luciferase data
reveal high level activity within this region (Fig. 3, A and B). A
nucleoprotein ternary complex of in vitro translated SRF and
MYOCD can readily be seen and validated with appropriate
antibodies to SRF and FLAG-tagged MYOCD (Fig. 4, lanes
5–7). Competitive EMSA experiments with cold205 probe or
CArG2 oligonucleotide disrupt CArG-SRF-MYOCD ternary
complex formation, whereas CArG1 or NKE have minimal
effect (Fig. 4, lanes 8–11). These results suggest that SRF-
MYOCD associate preferentially with CArG2 of the human
ACTG2 205 promoter.
We next evaluated effects of point mutations in each of the 4
CArG elements or NKE on the ability of MYOCD to transacti-
vate the ACTG2 promoter. Mutations in CArG1, -3, and -4,
leaving CArG2 intact, mildly reduce MYOCD transactivation
of the ACTG2 285 promoter (Fig. 5A). On the other hand,
mutating CArG2 in context of wild type CArG1, -3, and -4
completely abolishes MYOCD-dependent transactivation of
the ACTG2 promoter suggesting that CArG2 is the preferred
CArG element MYOCD utilizes for ACTG2 transcription (Fig.
5A). Surprisingly, mutation of NKE (without CArGmutations)
also reduces MYOCD-dependent transactivation suggesting
that NKE and one of its binding proteins may influence the
ability ofMYOCD to activate throughCArG2 (see below). Sim-
ilar results are seen in other cell types (L6 and HeLa) and with
the ACTG2 205 promoter (data not shown).
We next performed EMSA with the ACTG2 285 promoter
(with 4 CArG boxes) as a probe; chromatin immunoprecipita-
tions cannot adequately discriminate SRF-MYOCDassociation
between such closely juxtaposed CArG elements. We find that
mutation of all 4 CArGs is incompatible with SRF-MYOCD
ternary complex formation (Fig. 5B, lane 2 versus lane 1). Con-
sistent with the luciferase activity above, the same probe with
only CArG2 intact supports full binding activity (lane 3 versus
lane 1), but mutation of CArG2 in the context of WT CArG1/
FIGURE 1. ACTG2 expression in cell lines and tissues. A, RT-PCR analysis
showing mRNA expression of SMC -actin (Actg2) and other SMC markers and
transcription factors in various tissues and cell culture models. Note the wide-
spread expression of full-length (upper band) Srf but restricted expression of
the 5 splice variant (lower band) of Srf (47) to cultured cells and skeletal
muscle and heart, but not aortic medial SMC. B, RT-PCR analysis of the indi-
cated markers in various prostate cell lines treated with either 1 (Strom and
Epi) or 10 nM (PC-3 and LNCaP) androgen (R1881). Abbreviations used are
prostate stromal cells, Strom; and prostate epithelial cells, Epi. C, RT-PCR anal-
ysis of the indicated markers in prostate (Pr) and bladder (Bl). D, ACTG2 pro-
tein expression (brown) in coronary artery (d), aorta (e), and microvessels of rat
perivascular tissue (arrows in f). Specificity of staining is indicated by the
absence of signal when using an isotype-matched IgG control antibody (pan-
els a–c). Magnifications are 200.
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3/4 leads to near complete loss in SRF-MYOCD ternary com-
plex formation (lane 4). Competitive EMSA studies further
substantiate the pivotal role of CArG2 in SRF-MYOCDbinding
to the ACTG2 285 promoter (lanes 6–11). We next deter-
mined the effects of substituting CArG2 with other CArG ele-
ments on ACTG2 promoter activity and SRF-MYOCD com-
plex formation. Substantial loss in both promoter activity (Fig.
5C) and SRF-MYOCD ternary complex formation (Fig. 5B,
lanes 12–15) is seen when CArG2 is replaced with any of the
other CArG elements of theACTG2 promoter. Taken together,
results support the concept of MYOCD preferentially utilizing
a singleCArGelement (CArG2), amongmany, to effectACTG2
gene transcription.
NXK3.1 Potentiates ACTG2Promoter Activity and Physically
Associates with MYOCD—Because mutation of the NKE site
adjacent to CArG1 reduces MYOCD-dependent transactiva-
tion of the ACTG2 promoter (Fig. 5A), we hypothesized that
NKX3.1 would augment MYOCD-dependent ACTG2 pro-
moter activity. Initial co-transfection studies with NKX3.1 and
MYOCD failed to show any additive effect of NKX3.1 on
ACTG2 promoter activity, probably
because the level of MYOCD
expression was high thus masking
any positive effect of NKX3.1 (data
not shown). However, when we
reduce the concentration of
MYOCD 10-fold, a strong stimu-
latory effect of NKX3.1 is observed
in COS7 cells (Fig. 6A). This effect
requires MYOCD and is specific for
NKX3.1 as the related NKX2.5 fac-
tor is without effect (Fig. 6A) despite
its apparently higher expression
(Fig. 7A, lower panel). The effect of
NKX3.1 on MYOCD-dependent
transactivation is dose-dependent
(Fig. 6B) and specific for theACTG2
promoter as no such activity is seen
with other SMC promoters or the
ACTG2 95 promoter (data not
shown). Moreover, similar findings
are seen in HeLa and L6 cells indi-
cating the effects are not restricted
to only one cell type (data not
shown). Similar to data in Fig. 5A,
the synergistic stimulation for
NKX3.1 of the ACTG2 promoter
activity is severely attenuated when
either CArG2 or the NKE site is
mutated (Fig. 6C). Collectively, these
results suggest MYOCD functionally
associates with NKX3.1 to effect
ACTG2 transcription.
To ascertain whether the func-
tional association between NKX3.1
and MYOCD extends to a physical
interaction, we performed co-im-
munoprecipitations in COS7 cells
co-transfected with Myocd and Nkx3.1 or Nkx2.5. Both NKX
factors interact with MYOCD (Fig. 7A, middle panel) and the
interaction of NKX3.1 was lost when the C-terminal transacti-
vation domain of MYOCD was deleted (Fig. 7B,middle panel).
The direct interaction betweenMYOCD andNKX3.1 was con-
firmed by the in vitro binding assay of [35S]MYOCDwith GST-
NKX3.1 (Fig. 7C). These results strongly suggest that NKX3.1
mediates its MYOCD-dependent transactivation of ACTG2
transcription via direct physical contact through the C-termi-
nal transactivation domain of MYOCD.
DISCUSSION
The results of this report demonstrate expression of SM
-actin (ACTG2) in vascular SMC in vitro and in vivo, thereby
validating this traditionally viewed visceral SMCmarker (26), a
vascular SMC marker as well. The human ACTG2 promoter,
containing four conserved CArG elements, exhibits SMC-
specific promoter activity in vitro and is highly responsive to
MYOCD-dependent transactivation. Several lines of evidence
supportMYOCDpreferentially utilizing a singleCArGelement
FIGURE 2. Basal ACTG2 promoter activity. A, VISTA plot of the 9-exon human (Hsa) ACTG2 gene (denoted at
the top with the bent arrow indicating the transcription start site) versus orthologs in chimp (Ptr), dog (Cfa),
mouse (Mmu), and chicken (Gga). Blue vertical peaks indicate exons, whereas pink peaks indicate at least 75%
sequence homology over 100 bp of non-coding sequence. Note the progressive loss in non-coding sequence
homology from chimp to chicken. B, sequence logos for the 5 major cis-acting elements in the immediate 5
promoter region of ACTG2. These logos represent position weight matrices derived from human, chimp, dog,
mouse, and chicken orthologous sequence elements (position of human elements relative to transcription
start site indicated at the left of each logo). Note that CArG4 and CArG2 are 100% homologous across all species
analyzed. Where sequences diverge in other elements, the height of the letters diminishes with inclusion of
variant base sequences. C, firefly luciferase activities of various human ACTG2 promoter constructs in 3 distinct
SMC lines (PAC1 pulmonary artery, human SKLMS uterine SMC, and A7r5 aortic SMC) versus two non-SMC types
(COS7 and L6). Luciferase activity is presented here as the fold-activation of normalized (ratio of luciferase to
Renilla control) luciferase to the minimal 55 promoter, set to 1. Each bar represents the average (and standard
deviation) of 4 replicates in each of the indicated cells lines. These experiments were performed multiple times
with similar trends in relative fold-activation. Note the y axis here and in Fig. 3 is based on a logarithmic scale.
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for transactivation ofACTG2. First, we show throughmutagen-
esis studies that MYOCD mediates ACTG2 transcription pri-
marily through CArG2. Second, the CArG2 sequence is shown
to confer the highest level of SRF-MYOCD binding. Finally,
replacing CArG2 with another consensus CArG (CArG1) only
weakly activates the ACTG2 promoter demonstrating that the
sequence character of CArG2 is critical for MYOCD-depend-
ent transactivation.Mutation of a binding site for NKX3.1 (24),
adjacent to CArG2, reduces MYOCD-dependent transactiva-
tion of ACTG2, suggesting a functional association between
NKX3.1 and MYOCD. Indeed, we show that NKX3.1 potenti-
ates the activity of MYOCD in a CArG2- and NKE-dependent
manner, and binding assays reveal direct association ofNKX3.1
to the C-terminal domain of MYOCD. Taken in aggregate, the
results suggest a novel mechanism for the ability ofMYOCD to
discriminate amongmultiple CArG boxes through the physical
and functional association ofMYOCDwith the NKX3.1 home-
odomain protein.
In mammals, there are six major actin isoforms encoded by
separate genes that are transcribed as six independent tran-
scripts encoding proteins with 90% amino acid identity (30).
All six actin genes contain at least one SRF-binding CArG ele-
ment that is important for gene transcription (8), yet each gene
displays unique expression patterns during development and in
postnatal tissues (21, 31). The manner in which the ubiquitous
SRF transcription factor mediates such disparate patterns of
gene expression relates to its ability to recruit and bind context-
or cell-restricted transcription factors, some of which associate
with neighboring cis elements. For example, the cardiac-actin
(Actc1) promoter has CArG elements that bind SRF and
NKX2.5, both ofwhich counter the repressive effects of another
CArG-binding factor, YY1 (32). SRF and NKX2.5 physically
FIGURE 3. MYOCD-dependent stimulation of ACTG2 promoter and
endogenous mRNA. COS7 (A) or PAC1 SMC (B) were co-transfected with the
indicated human ACTG2 promoters linked to luciferase in the absence (open
bars) or presence (closed bars) of MYOCD and resulting activities determined
as described in the legend to Fig. 1. Similar results were found in two inde-
pendent experiments. C, semi-quantitative RT-PCR analysis shows endoge-
nous Actg2 mRNA induction in three independent L6 myoblast clones stably
transfected with Myocd, but not in similarly grown L6 cells carrying an empty
expression vector. A housekeeping gene (Gapd) serves as a loading control.
D, knockdown of SRF in BC3H1 cells reveals decreases in Actg2 mRNA expres-
sion. shEGFP, short hairpin enhanced green fluorescent protein (shEGFP).
FIGURE 4. SRF-MYOCD ternary complex formation on the ACTG2 pro-
moter. EMSA showing SRF/FLAG-MYOCD binding to a radiolabeled ACTG2
205 probe containing CArG2, CArG1, and NKE (labeled A, B, and C, respec-
tively, in the schematic at the bottom). The probe supports SRF binding (lane
2), which is supershifted with an antibody to SRF (lane 3), but not MYOCD
binding alone (lane 4). A ternary complex is seen when SRF and MYOCD are
combined (lane 5) and this complex is supershifted with antibodies to SRF
(lane 6) or FLAG (lane 7). Ternary complex is competed with the cold 205
probe (lane 8) or CArG2 (lane 9), but not CArG1 (lane 10) or NKE (lane 11)
oligonucleotides. Similar results are seen when using whole cell lysates of L6
myoblasts stably transfected with FLAG-MYOCD as the source of MYOCD
(data not shown).
FIGURE 5. ACTG2 CArG2 is the major determinant for SRF-MYOCD bind-
ing and activity. A, luciferase activities (normalized fold-change versus wild
type ACTG2 285 set to 1) in COS7 cells co-transfected with the indicated
mutant promoters and MYOCD. Each bar represents the average (and S.D.) of
4 replicates and is representative of several independent experiments.
B, EMSA of in vitro translated SRF and MYOCD with wild type and various
mutants of the ACTG2 285 promoter, used as radiolabeled probes. Presence
or absence of nucleoprotein complexes with wild type (lanes 1 and 6), mutant
CArG1– 4 (lane 2), mutant CArG1, -3, and -4 (lane 3), mutant CArG2 (lane 4), or
mutant NKE (lane 5) probes. Variable reductions in SRF-MYOCD nucleopro-
tein complexes with the 285 ACTG2 probe are seen with 100 cold com-
petitor oligonucleotides to CArG2 (lane 7), CArG1 (lane 8), CArG3 (lane 9),
CArG4 (lane 10), and NKE (lane 11). SRF-MYOCD complexes with wild type
285 ACTG2 probe (lane 12) and the same probe with CArG substitutions as
follows: CArG2  CArG1 (lane 13), CArG2  CArG3 (lane 14), or CArG2 
CArG4 (lane 15). C, luciferase activities (as in panel A) following MYOCD-de-
pendent activation of the indicated ACTG2 285 promoter constructs in
COS7 cells. Single and double asterisks indicate statistical significance at 0.05
and 0.01, respectively.
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associate and the latter is proposed to direct expression ofActc1
independent of its ability to bind DNA (33, 34). Thus, verte-
brate hearts express the cardiac isoformof actin largely through
the coordinate activities of SRF and heart-restricted factors
such as NKX2.5. The notable lack of NKX3.1 expression in
heart (35–37) could explain, in part, the weak expression of
Actg2 in the myocardium (36) (and Fig. 1) despite the presence
of MYOCD. These examples highlight a broader complex
regulation of SRF-dependent muscle-restricted genes through
the coordinate activities of over 60 SRF cofactors (8).
Previously we showed that a
proximal CArG box of the chicken
Actg2 promoter binds SRF avidly
through an interaction with NKX3.1
that binds an NKE adjacent to the
CArG box (24). In this report, we fur-
ther advance this concept by showing
a functional and physical interaction
betweenNKX3.1 andMYOCD. The
functional association of NKX3.1
with MYOCD appears to be unique
because a related homeodomain
protein (NKX2.5) binds MYOCD
but shows no activity over the
ACTG2 promoter. It is possible
that interactions between MYCOD
and NKX2.5 potentiate cardiac-re-
stricted genes.
Currently available assays could
not reveal the presence of a com-
plex between SRF, MYOCD, and
NKX3.1 (not shown); however, we
postulate that a multiprotein com-
plex encompassing these and per-
haps other factors over CArG2 and
NKE exists to optimally transacti-
vate the ACTG2 promoter in a con-
text-dependent fashion. One such
context may be the prostate epithe-
lium where levels of Nkx3.1 (35,
37–39), Actg2 (40), and possibly
Myocd (this report) are expressed.
Loss in NKX3.1 results in defects of
the prostate, including hyperplasia
of the ductal epithelium with no
obvious defects in vascular tissues
(38, 39). Whether levels of ACTG2
are reduced in the prostate or vascu-
lar tissues from Nkx3.1 null mice is
currently unknown. Interestingly,
ACTG2 andNKX3.1 are considered
tumor suppressors with the former
part of a molecular signature for
human metastatic disease (41).
MYOCD is also known to reduce
growth (4) and itself has been impli-
cated as a tumor suppressor (42).
Thus, it may be important to main-
tain normal levels ofNKX3.1, ACTG2, andMYOCD for normal
prostate function.
Although there are four closely spaced CArG boxes within
theACTG2 promoter, the two proximal sequences, CArG1 and
CArG2, are the most avid players with regard to MYOCD-me-
diated transcriptional responses. This would be consistent with
the concept advanced by Olson and colleagues (11) that pro-
poses MYOCD acting as a molecular bridge between adjacent
CArG boxes in CArG-rich promoters to mediate strong, cell-
specific transcription (43).However, there are exceptions to the
FIGURE 6. NKX3.1 potentiates MYOCD-dependent activation of the ACTG2 promoter. A, COS7 cells were
co-transfected with the ACTG2 285 promoter plus the indicated plasmids, and luciferase activity (per “Exper-
imental Procedures”) was measured 24 h later. The amount of MYOCD input was 50 ng, whereas NK factors
were used at 500 ng. Results are displayed as the mean  S.D. and are representative of two independent
studies. B, similar study as in panel A only the amount of NKX3.1 input was varied and balanced by the empty
pcGN vector control. C, the wild type ACTG2 285 promoter or the indicated mutants were co-transfected with
50 ng of MYOCD and 500 ng of NKX3.1 and luciferase activity measured (per “Experimental Procedures”).
Results are displayed as those in panels A and B.
FIGURE 7. Interaction of myocardin with NKX3.1 and NKX2.5. A and B, COS7 cells were transfected with
cDNAs for FLAG-tagged full-length myocardin (WT) or its truncated mutant with deleted C-terminal transacti-
vation domain (C) together with HA-tagged NKX3.1 or NKX2.5. Cells were lysed and the cleared cell extracts
were subjected to immunoprecipitation (IP) with FLAG antibodies followed by Western blotting (WB) of
immune complexes (IP) or total cell lysates with FLAG or HA antibodies. C, in vitro binding of [35S]MYOCD with
GST-Nkx3.1.
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multi-CArG, MYOCD responsive target gene concept includ-
ing Egr1 and Akap12 promoters, which contain multiple
CArG elements but are nevertheless refractory toMYOCD-de-
pendent transactivation (12, 14) (data not shown).Additionally,
there are single CArG-containing gene promoters, such as
telokin and Cald1, that are strongly activated by MYOCD (16,
44). Although the bulk of evidence supports the concept of
MYOCD-dependent gene activation requiring multiple CArG
sequences, the growing exceptions to this idea may indicate a
role for accessory proteins to potentiate or modify cell-specific
MYOCD-mediated responses. In the activation of Egr1 tran-
scription, there appears to be a competitive inhibition of
MYOCD response by association of ELK1 with SRF (13). As
indicated in our studies, MYOCD-mediated transcription of
ACTG2 is potentiated by its interaction with the homeodo-
main, NKX3.1. The functional consequences of this interaction
are dependent upon DNA context as shown by the inability of
NKX2.5-MYOCD complexes to activate ACTG2 promoters.
Thus our results support the concept that MYOCD-mediated
transcriptional responses requireCArGcontextwithin the pro-
moter/activator segment as well as the appropriate association
of multiple proteins within the transcriptional complex.
Two of the four CArG elements in the ACTG2 promoter
(CArG3 and CArG4) are non-consensus CArG boxes that bind
SRF weakly (26) and confer no further MYOCD-dependent
transactivation. Therefore, the ACTG2 promoter presents a
model to gain an understanding of MYOCD-modulated, cell-
specific transcriptional activation in promoters containing
active and inactive CArG elements. Similar to ACTG2, the
TAGLN promoter contains two similarly spaced CArG boxes
within its 5 proximal promoter. Although this gene is highly
MYOCD inducible, studies in transgenic mice have shown that
a single CArG box is responsible for cell-specific promoter
activity (45, 46), indicating that multiple CArGs may partici-
pate in gene activation through several mechanisms. Thus, it is
possible that the ACTG2 non-consensus CArG boxes play an
important context-dependent role in appropriate MYOCD/
SRF transcriptional responses. Of note is our previous studies
demonstrating a time- dependent binding of SRF toCArG3 and
CArG4 in SMC with elevated SRF expression (26). This would
indicate that promoter context plays a significant role in appro-
priate cell-specific transcription. That is, these distal elements
may potentiate ACTG2 transcription that was initiated by
MYOCD-dependent activation at the proximal CArG ele-
ments resulting in appropriate SMCACTG2 expression. Alter-
natively, theremay be little functionality of these sequences and
their conservation may simply reflect their juxtaposition to a
block of sequence resistant to genetic drift. It will be important
to address these questions in transgenicmice where each of the
ACTG2 CArG elements is mutated.
In summary, we provide new insight into the transcriptional
regulation of a CArG-rich human SMC-restricted promoter,
ACTG2. The finding that SRF and MYOCD utilize a distinct
CArG element, even among a cluster of similar elements over
a short genomic landscape, supports a model wherein the
sequence content of the CArG box, per se, imparts structural
information that dictates how SRF-associated factors such as
MYOCD interact.Molecular structure studies of different SRF-
CArG nucleoproteins in the absence or presence of MYOCD
will likely offer novel insight into how theCArG sequence char-
acter confers MYOCD-dependent transactivation.
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